189 related articles for article (PubMed ID: 22973555)
1. MAP17, a ROS-dependent oncogene.
Carnero A
Front Oncol; 2012; 2():112. PubMed ID: 22973555
[TBL] [Abstract][Full Text] [Related]
2. MAP17 enhances the malignant behavior of tumor cells through ROS increase.
Guijarro MV; Leal JF; Blanco-Aparicio C; Alonso S; Fominaya J; Lleonart M; Castellvi J; Ramon y Cajal S; Carnero A
Carcinogenesis; 2007 Oct; 28(10):2096-104. PubMed ID: 17548903
[TBL] [Abstract][Full Text] [Related]
3. p38α limits the contribution of MAP17 to cancer progression in breast tumors.
Guijarro MV; Vergel M; Marin JJ; Muñoz-Galván S; Ferrer I; Ramon y Cajal S; Roncador G; Blanco-Aparicio C; Carnero A
Oncogene; 2012 Oct; 31(41):4447-59. PubMed ID: 22266858
[TBL] [Abstract][Full Text] [Related]
4. MAP17 and the double-edged sword of ROS.
Carnero A
Biochim Biophys Acta; 2012 Aug; 1826(1):44-52. PubMed ID: 22465409
[TBL] [Abstract][Full Text] [Related]
5. MAP17 overexpression is a common characteristic of carcinomas.
Guijarro MV; Leal JF; Fominaya J; Blanco-Aparicio C; Alonso S; Lleonart M; Castellvi J; Ruiz L; Ramon Y Cajal S; Carnero A
Carcinogenesis; 2007 Aug; 28(8):1646-52. PubMed ID: 17426052
[TBL] [Abstract][Full Text] [Related]
6. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.
Guijarro MV; Link W; Rosado A; Leal JF; Carnero A
Carcinogenesis; 2007 Dec; 28(12):2443-50. PubMed ID: 17675338
[TBL] [Abstract][Full Text] [Related]
7. MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy.
Rivero M; Peinado-Serrano J; Muñoz-Galvan S; Espinosa-Sánchez A; Suarez-Martinez E; Felipe-Abrio B; Fernández-Fernández MC; Ortiz MJ; Carnero A
Oncotarget; 2018 Aug; 9(68):32958-32971. PubMed ID: 30250642
[TBL] [Abstract][Full Text] [Related]
8. MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
Muñoz-Galván S; Gutierrez G; Perez M; Carnero A
Mol Cancer Ther; 2015 Jun; 14(6):1454-65. PubMed ID: 25837675
[TBL] [Abstract][Full Text] [Related]
9. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.
de Miguel-Luken MJ; Chaves-Conde M; de Miguel-Luken V; Muñoz-Galván S; López-Guerra JL; Mateos JC; Pachón J; Chinchón D; Suarez V; Carnero A
Oncotarget; 2015 May; 6(14):12625-36. PubMed ID: 25788275
[TBL] [Abstract][Full Text] [Related]
10. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.
Perez M; Praena-Fernandez JM; Felipe-Abrio B; Lopez-Garcia MA; Lucena-Cacace A; Garcia A; Lleonart M; Roncador G; Marin JJ; Carnero A
PLoS One; 2013; 8(2):e56169. PubMed ID: 23418532
[TBL] [Abstract][Full Text] [Related]
11. The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
Garcia-Heredia JM; Lucena-Cacace A; Verdugo-Sivianes EM; Pérez M; Carnero A
Clin Cancer Res; 2017 Jul; 23(14):3871-3883. PubMed ID: 28153862
[No Abstract] [Full Text] [Related]
12. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).
Perez M; Peinado-Serrano J; Garcia-Heredia JM; Felipe-Abrio I; Tous C; Ferrer I; Martin-Broto J; Saez C; Carnero A
Oncotarget; 2016 Oct; 7(41):67033-67046. PubMed ID: 27563810
[TBL] [Abstract][Full Text] [Related]
13. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains.
Kocher O; Comella N; Tognazzi K; Brown LF
Lab Invest; 1998 Jan; 78(1):117-25. PubMed ID: 9461128
[TBL] [Abstract][Full Text] [Related]
14. Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells.
García-Heredia JM; Otero-Albiol D; Pérez M; Pérez-Castejón E; Muñoz-Galván S; Carnero A
Oncogenesis; 2020 Oct; 9(10):96. PubMed ID: 33106480
[TBL] [Abstract][Full Text] [Related]
15. MAP17 Expression in Colorectal Cancer Is a Prognostic Factor for Disease Recurrence and Dismal Prognosis Already in Early Stage Disease.
Tampakis A; Tampaki EC; Nonni A; Kontos M; Tsourouflis G; Posabella A; Fourie L; Bolli M; Kouraklis G; von Flüe M; Felekouras E; Nikiteas N
Oncology; 2021; 99(7):471-482. PubMed ID: 33853080
[TBL] [Abstract][Full Text] [Related]
16. Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrest.
Guijarro MV; Castro ME; Romero L; Moneo V; Carnero A
J Cell Biochem; 2007 May; 101(1):112-21. PubMed ID: 17230460
[TBL] [Abstract][Full Text] [Related]
17. The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment.
García-Heredia JM; Carnero A
Oncotarget; 2017 Nov; 8(58):98580-98597. PubMed ID: 29228712
[TBL] [Abstract][Full Text] [Related]
18. EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
Shao Y; Lv H; Zhong DS; Zhou QH
Oncol Lett; 2018 May; 15(5):6655-6665. PubMed ID: 29616128
[TBL] [Abstract][Full Text] [Related]
19. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth.
Kocher O; Cheresh P; Lee SW
Am J Pathol; 1996 Aug; 149(2):493-500. PubMed ID: 8701988
[TBL] [Abstract][Full Text] [Related]
20. Interactions of MAP17 with the NaPi-IIa/PDZK1 protein complex in renal proximal tubular cells.
Pribanic S; Gisler SM; Bacic D; Madjdpour C; Hernando N; Sorribas V; Gantenbein A; Biber J; Murer H
Am J Physiol Renal Physiol; 2003 Oct; 285(4):F784-91. PubMed ID: 12837682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
